Navigation Links
SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern
Date:4/29/2009

BOTHELL, Wash., April 29 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced plans to release first quarter 2009 financial results on Friday, May 1, 2009, at 8:30 a.m. Eastern. Dr. Bruce S. Morra, President and CEO of SCOLR Pharma, will host the conference call at 11:30 a.m. Eastern, to discuss the Company's results for the quarter.

Shareholders and other interested parties may participate in the conference call by dialing +1 888 713 4217 (domestic) or +1 617 213 4869 (international) and entering access code 55195099, a few minutes before 11:30 a.m. ET on May 1, 2009. The call will also be broadcast live on the Internet at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

A replay of the conference call will be accessible two hours after its completion through May 15, 2009, by dialing +1 888 286 8010 (domestic) or +1 617 801 6888 (international) and entering access code 86289597. The call will also be archived for 90 days at www.streetevents.com, www.fulldisclosure.com or www.scolr.com.

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company whose objective is to combine its formulation expertise and its patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutr
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. SCOLR Pharma, Inc. Announces Engagement of HealthPro as Financial Advisor
2. SCOLR Pharma, Inc. Schedules Fourth Quarter 2008 Financial Results Conference Call for March 11, 2009 at 11:30 A.M. Eastern
3. SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO
4. SCOLR Pharma, Inc. Announces Resignation of CEO Daniel O. Wilds
5. SCOLR Pharma, Inc. Announces Positive Top-Line Results From Pivotal Clinical Trial Evaluating Efficacy of Extended-Release Ibuprofen
6. SCOLR Pharma, Inc. Schedules Third Quarter 2008 Financial Results Conference Call for November 7, 2008 at 11:30 A.M. Eastern
7. SCOLR Pharma, Inc. Submits Abbreviated New Drug Application for a 12-hour CDT-based Pseudoephedrine Formulation
8. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
9. China Biopharma, Inc. Issues Corporate Information Update
10. Why Do Drugs Cost So Much? and why are we so darn sick?: New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health
11. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Hands On Mobile Spa, has announced they now have a ... been transformed into a utopia for the Long Island community ... The Virtual Tour showcases the beauty of the Spa On ... more. , The Virtual Tour shows viewers each of the ... overhauled Winnebago. Marla Kaplan-Pelle, Director states " It's hard to ...
(Date:12/19/2014)... December 19, 2014 After a 13-year ... is again returning to the stage to entertain his ... for concert performances, and the successful tour has been ... announced. , Visit Ticketability.com for a ... Detroit shows at fair prices. , Music fans have ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- A new study ... moderate to severe hot flashes and night sweats -- ... Hot flashes are common during menopause, affecting about ... also affect women after menopause, since they then face ... "Our findings suggest women who exhibit moderate or severe ...
(Date:12/19/2014)... News) -- Prostaglandin analogue eye drops -- a common ... of vision loss in patients with the eye disease, ... David Garway-Heath, of the Moorfields Eye Hospital and UCL ... than 500 people newly diagnosed with open-angle glaucoma -- ... of the leading causes of blindness. About 45 ...
(Date:12/17/2014)... RI (PRWEB) December 17, 2014 ... recognize private practices that have made outstanding and ... in support and progression of private practice physical ... American Physical Therapy Association. , On behalf of ... OCS, owner and CEO of Performance accepted the ...
Breaking Medicine News(10 mins):Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... minister Andy Kerr has ordered the closure of two hospitals ... close the hospitals in the border as part of a ... the 80-year-old nine-bed Queen Margaret Hospital in Jedburgh and the ... worked hard to save the community hospitals. The Jedburgh Provost ...
... of laws was initiated by Quebec Health Minister Philippe Couillard ... health-care insurance //. ,The Supreme Court of Canada ... on June 9, 2005,ruling that Quebec had failed to prove ... medicare, was justified. However with the development of Bill ...
... fast-growing medical tourism industry is set to get a ... the entire range of medicare facilities overseas//. ,Global ... a leading travel firm, have signed an agreement to ... Africa, Canada and the Middle East. ...
... study has shed light on a different dimension to ... during childhood. // Insecure feelings experienced during childhood and ... of one’s body that can translate into an eating ... very early due to insecure attachment and separation anxiety. ...
... women, women overweight in their teens or later are at ... was conducted by scientists at the University of Pittsburgh Medical ... 2,110 women with and without ovarian cancer. The study of ... in recent years or at the age of 18, were ...
... boy’s divorced parents, whether to circumcise their son or not. ... inflammation in last year, his mother needs her son to be ... is fine and if circumcision was done it will result in ... 2003 divorce decree has given the rights to decide on the ...
Cached Medicine News:Health News:Quebecers To Choose Private Health-Care Insurance 2Health News:Plan to Promote the Medicare Facilities of India to Abroad 2
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... , Dec. 15, 2014  Inovio Pharmaceuticals, Inc. ... has been added to the NASDAQ Biotechnology Index ... will become effective upon market open on December ... is designed to track the performance of a ... either biotechnology or pharmaceutical according to the Industry ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... 18, 2011 What:   ... analysis of FDA,s 510(k) regulatory pathway—through which more than ... within it. The study is the most comprehensive survey ... FDA,s Center for Devices and Radiological Health (CDRH) is ...
... DIEGO, May 18, 2011 aTyr Pharma ... that Melissa Ashlock, M.D., has joined as vice ... Ashlock,s experience in translating novel biology into drug ... team in the development of innovative therapeutic approaches ...
Cached Medicine Technology:Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics 2Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics 3
Karlin XL Magnum Cup Curettes, extra long (XL) curettes, black handles, lightweight, length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Medicine Products: